Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
Charlotte C van RuitenAnnemarie B van der Aart-van der BeekRichard G IJzermanMax NieuwdorpKlaas HoogenbergDaniel H van RaalteHiddo J Lambers HeerspinkPublished in: Diabetes, obesity & metabolism (2021)
This prespecified secondary analysis suggests that combined therapy with exenatide and dapagliflozin may have synergistic effects on markers of kidney function compared to either therapy alone or placebo in obese patients with type 2 diabetes.